India regulatory affairs

Your regulatory
representative in India

A sponsor without an Indian entity files through one. Applications to the Central Drugs Standard Control Organisation are made and answered by a party established in India, and the regulator’s own approval records show foreign sponsors filing through an Indian applicant. We are that party, and we work for you rather than for the vendor running your study. We prepare and file the application, carry the ethics committee submissions and the import licence, and hold the file for as long as the trial runs.

Speak to us →
For sponsors outside India

Clinical trials in India

We are appointed as the sponsor’s representative and deal with the regulator on its behalf, from the first application through to the queries that follow.

Represent you to CDSCO
Named as your authorised representative, dealing with the Central Drugs Standard Control Organisation directly, under written authorisation and defined scope.
File the trial application
The clinical trial application prepared and filed, the regulatory pathway agreed before the dossier is assembled, and every query answered through to approval.
Clear the ethics committees
Submission packages prepared for each site’s registered ethics committee and the correspondence carried to approval.
Import your investigational product
Licence applications for the import of investigational product, and the local safety reporting that runs alongside the trial.
Read a protocol for India
What India will require of your protocol, established before you select a site or fix a budget.
Choose and audit your CRO
We select and oversee contract research organisations on your behalf. We are not one, so we audit one without a conflict.

An appointment here runs for years, not for one submission. Indian regulatory permissions are granted for fixed terms and renewed — an import licence for investigational product runs three years — and changing the party named on a file means re-filing it. The representative appointed at the start is the one who answers every query that follows. Appointing your importer or distributor to the role puts a commercial counterparty on your regulatory file. We do not distribute the product we register.

For Indian manufacturers

Market entry abroad

Taking an Indian generic into the United States, Canada, the European Union, the United Kingdom and India — dossier, filing strategy and timing, worked per destination market rather than as one submission repeated five times.

Choose the market and the route
Which markets a product can realistically enter, by which regulatory route, and in what order — decided before the first dossier is built.
Build the dossier
Dossiers prepared to each destination’s own requirements and format, ready for the marketing authorisation holder to file.
Time it against expiry
We hold patent and exclusivity records from the published registers of the United States, the European Union and Canada, and work backwards from them so a filing is ready rather than started when protection ends.
Keep it approved
Variations when a site, a specification or a supplier changes; renewals to each market’s timetable; and reviews of dossiers that have fallen behind the market they sit in.
How we price. Variation dossiers and renewal submissions are quoted as a fixed fee per dossier, per market — not by the hour. Change-classification opinions are a flat rate. You receive a written quote before any work begins, and it does not move unless the scope does.

We do not bill for time spent understanding your product.
Reference

India’s pharmaceutical exports, in published data

A compilation of India’s pharmaceutical export, patent and destination data, drawn from official statistical sources and public filings. Sources, bases and as-of dates are set out on the data and sources page.

Speak to us

We represent sponsors before the Indian regulator and take Indian generics into the United States, Canada, the European Union and the United Kingdom. Tell us about the product or the protocol and we will tell you what it takes.

Write to us directly at enquiries@worldmeds.org.